Information Provided By: 
Fly News Breaks for March 15, 2016
GWPH
Mar 15, 2016 | 08:53 EDT
BofA/Merrill raised GW Pharmaceuticals price target to $175 following positive topline data from its first Phase 3 trial of Epidiolex in Dravet Syndrome. Analyst Tazeen Ahmad said the result lift a major overhang for shares and raised his likelihood of approval in Dravet's to 60% from 40% and reiterated his Buy rating.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
